Although molecular subtypes such as HER2-positive and triple-negative breast cancers are well-established predictors of subsequent breast cancer event patterns and clinical outcomes [38,39], their impact was not statistically significant in our analysis. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.